Is Thermo Fisher Scientific (TMO) Pricing Look Stretched After Recent Share Price Rebound

• If you are wondering whether Thermo Fisher Scientific at around US$496 a share is good value or fully priced, the answer depends on how you look at the business and its cash flows.
• The stock has returned 0.9% over the last 7 days and 6.8% over the last 30 days, while year to date it is down 16.3% and up 13.6% over the last year, a mix that can change how the market is thinking about both growth potential and risk.
• Recent attention on Thermo Fisher Scientific has focused on its role in life sciences tools and services, with investors weighing how demand for research, diagnostics and bioprocessing products could evolve. This backdrop helps explain why some see the recent price moves as a reset in expectations rather than a simple short term swing.
• On Simply Wall St's valuation checks, Thermo Fisher Scientific scores 3 out of 6. The next sections will compare what different valuation approaches imply for the stock and then circle back to a more complete way of thinking about value that many investors overlook.

Thermo Fisher Scientific delivered 13.6% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes a company’s projected future cash flows and discounts them back to today using a required rate of return, giving an estimate of what the business might be worth right now.

For Thermo Fisher Scientific, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is around $6.3b. Simply Wall St uses analyst estimates where available, then extrapolates beyond that. In this case, projected free cash flow moves to around $7.4b in 2035, with interim years generally in the $6.1b to $7.1b range on the raw projections, all in US$ terms.

When these future cash flows are discounted back to today, the DCF model produces an estimated intrinsic value of about $304.61 per share. Compared with the recent share price of roughly $496, the model suggests the stock is around 62.9% above this DCF estimate, which points to a rich valuation on this specific cash flow set up.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific may be overvalued by 62.9%. Discover 58 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Thermo Fisher Scientific.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For a profitable company like Thermo Fisher Scientific, the P/E ratio is a useful way to think about value because it links what you pay for each share to the earnings that support that share. In broad terms, higher growth expectations and lower perceived risk tend to justify a higher P/E, while slower growth or higher uncertainty usually point to a lower “normal” or “fair” P/E range.

Thermo Fisher Scientific currently trades on a P/E of about 27.5x. That sits below the Life Sciences industry average P/E of around 33.9x and also below the peer group average of about 33.0x. On simple comparisons, the stock screens as cheaper than those benchmarks.

Simply Wall St’s Fair Ratio concept goes a step further. It estimates what a suitable P/E might be for Thermo Fisher Scientific specifically, after factoring in elements like earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it is tailored to the company, this approach can be more informative than using broad industry or peer averages, which may bundle together businesses with very different quality or risk profiles.

In this case, the Fair Ratio estimate is not available, so it is not possible to use this framework to say whether the current 27.5x P/E looks overvalued, undervalued, or about right.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring that idea to life by letting you attach a clear story about Thermo Fisher Scientific to the numbers you care about, such as your own fair value, revenue, earnings and margin estimates.

A Narrative on Simply Wall St links three pieces together: the business story you believe, the financial forecast that follows from it, and the fair value that drops out of those assumptions so you can compare it with today’s share price.

On the Community page, where millions of investors share views, Narratives are set up as easy to use templates. You can pick or tweak assumptions rather than build a model from scratch, then see whether your view points to a price that is above or below your fair value.

These Narratives update automatically when new data arrives, for example earnings reports or Thermo Fisher Scientific news, so the fair value you see is always tied to the latest information instead of a static snapshot.

For Thermo Fisher Scientific right now, one published Narrative uses a fair value of about US$540 per share, another more optimistic Narrative uses about US$738 per share, and a more cautious view sits at about US$575. This shows how different stories and forecasts can still be compared on one simple price versus fair value scale.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com